Evidence map›Paper›PMID 36212476›Full record

ArticleFrontiers in oncology2022

LncRNA MALAT1 regulates METTL3-mediated PD-L1 expression and immune infiltrates in pancreatic cancer.

Zhengwei Song, Xiaoguang Wang, Fei Chen, Qiuli Chen, Wenjun Liu, Xiaodan Yang, Xun Zhu, Xiaorong Liu, Peter Wang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 47 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Early cancer diagnosisWorld journal of gastrointestinal oncology · 2025
    Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Potential regulatory role of the mActa biochimica et biophysica Sinica · 2025
    Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Zhengwei SongDepartment of Surgery, The Second Affiliated Hospital of Jiaxing University, Jiaxing, China.
Xiaoguang WangDepartment of Surgery, The Second Affiliated Hospital of Jiaxing University, Jiaxing, China.
Fei ChenDepartment of Surgery, The Second Affiliated Hospital of Jiaxing University, Jiaxing, China.
Qiuli ChenDepartment of Research and Development, Zhejiang Zhongwei Medical Research Center, Hangzhou, China.
Wenjun LiuDepartment of Research and Development, Zhejiang Zhongwei Medical Research Center, Hangzhou, China.
Xiaodan YangDepartment of Surgery, The Second Affiliated Hospital of Jiaxing University, Jiaxing, China.
Xun ZhuDepartment of Surgery, The Second Affiliated Hospital of Jiaxing University, Jiaxing, China.
Xiaorong LiuDepartment of Surgery, The Second Affiliated Hospital of Jiaxing University, Jiaxing, China.
Peter WangDepartment of Research and Development, Zhejiang Zhongwei Medical Research Center, Hangzhou, China.
Jiaxing University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic cancer is the fourth leading cause of cancer death in the United States. The main methods of treating pancreatic cancer are surgery and chemotherapy, but the treatment efficacy is low with a poor prognosis. Immunotherapy represented by PD-1/PD-L1 has brought a milestone progress in the treatment of pancreatic cancer. However, the unique tumor microenvironment of pancreatic cancer presents challenges for immunotherapy. In addition, m6A is a common RNA modification and a potential molecular target in tumor therapy. The expression pattern of m6A in pancreatic cancer is still unclear. LncRNAs also play an essential role in pancreatic cancer development and treatment. In this study, we found that some m6A regulators were significantly elevated in pancreatic cancer and associated with the expression of PD-1/PD-L1. Moreover, we observed that METTL3 can increase the expression of PD-L1. Notably, METTL3 positively regulates the expression of lncRNA MALAT1 in pancreatic cancer cells. Strikingly, lncRNA MALAT1 increased the expression of PD-L1 in pancreatic cancer cells. This finding indicated that METTL3 regulated the expression of PD-L1 possibly

Indexed as

lncRNAMALAT1METTL3pancreatic cancerPD-L1TME

Identifiers

PMID36212476
PMCPMC9533337
OpenAlexW4296737721

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.